A Phase 1 interventional study of Eplereone in Atrial Fibrillation, sponsored by Assiut University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.
Sponsored by Assiut University · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing amiodarone in Atrial Fibrillation — 12 open to participants now, 12 under way, 3 of them phase 3. Amiodarone · Atrial Fibrillation.
Among the 46 studies testing amiodarone in Atrial Fibrillation, this one is the 28th largest by planned enrollment, is one of 6 that started in 2024, is the only one in phase 1, reaches primary completion later than 0 of the 11 other live ones, and was the 40th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →12 of the 46 studies testing amiodarone in Atrial Fibrillation are open now, in 8 countries. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Population Health Research Institute · Sites in Canada
Ages 18+
Hippocration General Hospital · Sites in Greece
Ages 18–85
Stanford University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Amiodarone: first FDA approval 1985 (CORDARONE). What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 13 · Phase 4 20
First in 1998; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 124 across the 46 interventional studies. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 46 has an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
14 studies in Atrial Fibrillation by Assiut University: 6 open now, 6 under way, none of them phase 3. Of 1 finished, 0 (0%) have results posted.
Among the 14 studies in Atrial Fibrillation by Assiut University, this one is one of 2 that started in 2024, is one of 2 in phase 1, and was the 10th registered.
Assiut University’s Atrial Fibrillation studies by the year they started, since 2015.
2 of the studies testing amiodarone in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07487714Tomsk National Research Medical Center of the Russian Academy of SciencesComparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration | 2027-05 |
| NCT06067438OHSU Knight Cancer InstituteAmiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer | 2027-08-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies testing amiodarone in Atrial Fibrillation, from their registry updates:
Among Assiut University’s 14 in Atrial Fibrillation:
This tab as a report to print or save as PDF → With an account.
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.
This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital, on 100 patients with AF and structural heart disease. AF is confirmed by electrocardiography. The patients were divided into 2 groups:
Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Group B (control group): 50 patients received amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Were given Eplereone 25 mg daily
Drug: Eplereone
Were given nothing
Drug: Eplereone
Group A (study group): 50 patients received eplerenon 25 mg daily plus amiodarone and other medications not including non-dihydropyridine calcium channel blocker or digoxin.
Also known as: Amiodarone
AF recurrence
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2024.
Of 20 phase 1 interventional studies under Atrial Fibrillation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 20. This study's planned 0 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amiodarone